Allinky
  • Home
  • Company
    • Our values
  • Our Approach
  • Our innovation
  • Disease Areas
    • 01 Autoinflammatory diseases
    • 02 Inflammation-related fibrosis
  • Pipeline
  • Investors
  • News
  • Contact
  • Menu Menu
News

Prof. Juan Jesús Gómez-Reino recognised for a lifetime of outstanding contribution to rheumatology

April 23, 2026

Allinky is pleased to share the recent recognition of Juan Jesús Gómez‑Reino, co‑founder of the company and member of its Advisory Board, for his outstanding career and contributions in the field of rheumatology.

This acknowledgement, granted by the Spanish Society of Rheumatology (SER), highlights his long‑standing career as a clinician, educator, and researcher, as well as his scientific leadership and impact on the understanding and treatment of inflammatory diseases. His professional trajectory reflects a sustained commitment to excellence and patient‑centered research, establishing him as a leading authority in the field of rheumatology.

Allinky congratulates Juan Jesús Gómez‑Reino on this well‑deserved recognition.

Boletín SER: Fallo “Maestro/a de la Reumatología”

Share this entry
  • Share on Facebook
  • Share on X
  • Share on WhatsApp
  • Share on LinkedIn
  • Share by Mail
https://allinky.com/wp-content/uploads/2026/04/Juan-Gomez-Reino-reconocimiento-SER.jpg 654 528 asun.burguete@allinky.com https://allinky.com/wp-content/uploads/2024/05/Logo-Allinky-480px.png asun.burguete@allinky.com2026-04-23 09:03:382026-04-28 09:17:07Prof. Juan Jesús Gómez-Reino recognised for a lifetime of outstanding contribution to rheumatology

SOCIAL

  • linkedin

RECENT POST

  • Prof. Juan Jesús Gómez-Reino recognised for a lifetime of outstanding contribution to rheumatologyApril 23, 2026 - 9:03 am
  • The inhibition of Il1β synthesis mediated by a novel pyridine-sulfonamide compound protects against the progression of metabolic dysfunction-associated steatotic liver diseaseFebruary 2, 2026 - 11:15 am
  • Allinky secures patent grant in ChinaJanuary 24, 2025 - 11:16 am
  • U.S. Patent granted to AllinkySeptember 6, 2024 - 8:18 am

Privacy Policy     Legal Notice     Cookie Policy

Allinky Biopharma Logo
The inhibition of Il1β synthesis mediated by a novel pyridine-sulfonamide compound...
Scroll to top
Manage consent

To offer the best experiences, we use technologies such as cookies to store and/or access device information. Consent to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent, or withdrawal of consent, may adversely affect certain features and functions.

Functional Always active
Storage or technical access is strictly necessary for the legitimate purpose of allowing the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network. .
preferences
Technical storage or access is necessary for the legitimate purpose of storing preferences not requested by the subscriber or user.
Statistics
Storage or technical access that is used exclusively for statistical purposes. El almacenamiento o acceso técnico que se utiliza exclusivamente con fines estadísticos anónimos. Sin un requerimiento, el cumplimiento voluntario por parte de tu proveedor de servicios de Internet, o los registros adicionales de un tercero, la información almacenada o recuperada sólo para este propósito no se puede utilizar para identificarte.
Marketing
El almacenamiento o acceso técnico es necesario para crear perfiles de usuario para enviar publicidad, o para rastrear al usuario en una web o en varias web con fines de marketing similares.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
See preferences
{title} {title} {title}